Methsuximide

Generic name: Pronounced as (meth sux' i mide)
Brand names
  • Celontin®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 04/15/2017

Methsuximide is used to control absence seizures (petit mal; a type of seizure in which there is a very short loss of awareness during which the person may stare straight ahead or blink his eyes and does not respond to others) that cannot be treated with other medications. Methsuximide is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.

Methsuximide comes as a capsule to take by mouth. It is usually taken one or more times a day. Take methsuximide at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take methsuximide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor will probably start you on a low dose of methsuximide and gradually increase your dose, not more often than once a week.

Methsuximide may help control your condition but will not cure it. Continue to take methsuximide even if you feel well. Do not stop taking methsuximide without talking to your doctor, even if you experience side effects such as unusual changes in behavior or mood. If you suddenly stop taking methsuximide, your seizures may worsen. Your doctor will probably decrease your dose gradually.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Before taking methsuximide,

  • tell your doctor and pharmacist if you are allergic to methsuximide, ethosuximide (Zarontin), or any other medications.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention antidepressants; other medications for seizures such as phenobarbital and phenytoin (Dilantin); medications for pain; sedatives; sleeping pills; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had mental illness or kidney or liver disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking methsuximide, call your doctor.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking methsuximide.

  • you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

  • talk to your doctor about the safe use of alcohol while you are taking this medication.

  • you should know that your mental health may change in unexpected ways and you may become suicidal (thinking about harming or killing yourself or planning or trying to do so) while you are taking methsuximide. A small number of adults and children 5 years of age and older (about 1 in 500 people) who took anticonvulsants such as methsuximide to treat various conditions during clinical studies became suicidal during their treatment. Some of these people developed suicidal thoughts and behavior as early as one week after they started taking the medication. There is a risk that you may experience changes in your mental health if you take an anticonvulsant medication such as methsuximide, but there may also be a risk that you will experience changes in your mental health if your condition is not treated. You and your doctor will decide whether the risks of taking an anticonvulsant medication are greater than the risks of not taking the medication. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: panic attacks; agitation or restlessness; new or worsening irritability, anxiety, or depression; acting on dangerous impulses; difficulty falling or staying asleep; aggressive, angry, or violent behavior; mania (frenzied, abnormally excited mood); talking or thinking about wanting to hurt yourself or to end your life; withdrawing from friends and family; preoccupation with death and dying; giving away prized possessions; or any other unusual changes in behavior or mood. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Methsuximide may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • vomiting

    • constipation

    • diarrhea

    • stomach pain

    • loss of appetite

    • weight loss

    • hiccups

    • headache

    • drowsiness

    • dizziness

    • difficulty coordinating movements

    • confusion

    • slowed thinking

    • unreasonable fear of developing a serious illness

    • swollen eyelids

    • blurred vision

    • sensitivity to light

  • If you experience any of the following symptoms, call your doctor immediately:

    • sore throat, fever, chills, and other signs of infection

    • joint pain or swelling

    • muscle pain

    • red, itchy rash, especially on the face

    • fever with no known cause

    • hives

    • blisters

  • Methsuximide may cause other side effects. Call your doctor if you have any unusual problems while you are taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature, away from light, excess heat, and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your response to methsuximide.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Moxifloxacin.
Repaglinide Repaglinide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Repaglinide.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin glargine.
Delavirdine Delavirdine The metabolism of Methsuximide can be decreased when combined with Delavirdine.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Dolasetron.
Aminophylline Aminophylline Methsuximide may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Anagrelide.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Methsuximide.
Candesartan Candesartan The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Candesartan.
Cilostazol Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Methsuximide.
Clopidogrel Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Methsuximide.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methsuximide.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Methsuximide.
Fenofibrate Fenofibrate The metabolism of Methsuximide can be decreased when combined with Fenofibrate.
Guanfacine Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.
Magnesium Gluconate Magnesium Gluconate The risk or severity of hypotension can be increased when Methsuximide is combined with Magnesium gluconate.
Magnesium Hydroxide Magnesium Hydroxide The risk or severity of hypotension can be increased when Methsuximide is combined with Magnesium hydroxide.
Magnesium Oxide Magnesium Oxide The risk or severity of hypotension can be increased when Methsuximide is combined with Magnesium oxide.
Miglitol Miglitol The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Miglitol.
Naratriptan Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Methsuximide.
Olsalazine Olsalazine The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Methsuximide.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.
Penbutolol Penbutolol The risk or severity of bradycardia can be increased when Methsuximide is combined with Acebutolol.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methsuximide.
Potassium Potassium Potassium cation may increase the hyperkalemic activities of Methsuximide.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Methsuximide.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Methsuximide.
Rizatriptan Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Methsuximide.
Sumatriptan Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Methsuximide.
Tacrolimus Tacrolimus Tacrolimus may increase the immunosuppressive activities of Methsuximide.
Tizanidine Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.
Zolmitriptan Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Methsuximide.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Methsuximide.
Fluconazole Injection Fluconazole Injection The metabolism of Methsuximide can be decreased when combined with Fluconazole.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Methsuximide.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Levofloxacin.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Methsuximide.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Methsuximide.
Metronidazole Injection Metronidazole Injection The therapeutic efficacy of Methsuximide can be decreased when used in combination with Metronidazole.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.
Altretamine Altretamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Methsuximide.
Cyclosporine Cyclosporine The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cyclosporine.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ondansetron.
Enoxaparin Injection Enoxaparin Injection The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Methsuximide.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Granisetron.
Olanzapine Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Methsuximide.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Methsuximide.
Dofetilide Dofetilide Methsuximide may increase the arrhythmogenic activities of Dofetilide.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Methsuximide.
Eprosartan Eprosartan The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Methsuximide.
Hydroxychloroquine Hydroxychloroquine The therapeutic efficacy of Methsuximide can be decreased when used in combination with Hydroxychloroquine.
Meloxicam Meloxicam The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Methsuximide.
Orlistat Orlistat Orlistat can cause a decrease in the absorption of Methsuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxcarbazepine Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Methsuximide.
Pantoprazole Pantoprazole The metabolism of Methsuximide can be decreased when combined with Pantoprazole.
Telmisartan Telmisartan The metabolism of Methsuximide can be decreased when combined with Telmisartan.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Methsuximide.
Anakinra Anakinra The metabolism of Methsuximide can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide.
Linezolid Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Methsuximide.
Rivastigmine Rivastigmine Rivastigmine may increase the bradycardic activities of Methsuximide.
Trimipramine Trimipramine The metabolism of Methsuximide can be decreased when combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Methsuximide can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil Modafinil The metabolism of Methsuximide can be decreased when combined with Modafinil.
Perindopril Perindopril The risk or severity of hyperkalemia can be increased when Perindopril is combined with Methsuximide.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The risk or severity of hyperkalemia can be increased when Choline magnesium trisalicylate is combined with Methsuximide.
Sirolimus Sirolimus Methsuximide may increase the immunosuppressive activities of Sirolimus.
Eplerenone Eplerenone The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Methsuximide.
Escitalopram Escitalopram The risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.
Olmesartan Olmesartan The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Methsuximide.
Zonisamide Zonisamide Zonisamide may increase the arrhythmogenic activities of Methsuximide.
Adalimumab Injection Adalimumab Injection The metabolism of Methsuximide can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methsuximide.
Atomoxetine Atomoxetine The risk or severity of adverse effects can be increased when Atomoxetine is combined with Methsuximide.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Methsuximide is combined with Dexmethylphenidate.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Methsuximide.
Almotriptan Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Methsuximide.
Eletriptan Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Methsuximide.
Mefloquine Mefloquine The therapeutic efficacy of Methsuximide can be decreased when used in combination with Mefloquine.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methsuximide.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Methsuximide.
Alfuzosin Alfuzosin The risk or severity of hypotension can be increased when Alfuzosin is combined with Methsuximide.
Aprepitant Aprepitant The metabolism of Methsuximide can be decreased when combined with Aprepitant.
Memantine Memantine The metabolism of Methsuximide can be decreased when combined with Memantine.
Tegaserod Tegaserod The therapeutic efficacy of Tegaserod can be decreased when used in combination with Methsuximide.
Frovatriptan Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Methsuximide.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Gemifloxacin.
Progesterone Progesterone The metabolism of Methsuximide can be increased when combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Methsuximide.
Infliximab Injection Infliximab Injection The metabolism of Methsuximide can be increased when combined with Infliximab.
Protriptyline Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.
Rifaximin Rifaximin The metabolism of Methsuximide can be increased when combined with Rifaximin.
Duloxetine Duloxetine The risk or severity of adverse effects can be increased when Methsuximide is combined with Duloxetine.
Norethindrone Norethindrone The metabolism of Norethisterone can be increased when combined with Methsuximide.
Trospium Trospium Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Erlotinib.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Methsuximide is combined with Eszopiclone.
Ganciclovir Ganciclovir The therapeutic efficacy of Methsuximide can be decreased when used in combination with Ganciclovir.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin aspart.
Solifenacin Solifenacin Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Valganciclovir Valganciclovir The therapeutic efficacy of Methsuximide can be decreased when used in combination with Valganciclovir.
Voriconazole Voriconazole The metabolism of Methsuximide can be decreased when combined with Voriconazole.
Dextroamphetamine Dextroamphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Methsuximide.
Pramlintide Injection Pramlintide Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Pramlintide.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Exenatide Injection Exenatide Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Exenatide.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methsuximide.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methsuximide.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Methsuximide.
Darifenacin Darifenacin Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Methsuximide.
Pregabalin Pregabalin The therapeutic efficacy of Methsuximide can be increased when used in combination with Pregabalin.
Phenylephrine Phenylephrine The risk or severity of hypertension can be decreased when Methsuximide is combined with Phenylephrine.
Tipranavir Tipranavir The metabolism of Methsuximide can be decreased when combined with Tipranavir.
Felbamate Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Methsuximide.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin detemir.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Methsuximide can be increased when combined with Abatacept.
Rasagiline Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Methsuximide.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Imatinib.
Sitagliptin Sitagliptin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Sitagliptin.
Gefitinib Gefitinib The metabolism of Methsuximide can be decreased when combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Methsuximide.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Paliperidone.
Bortezomib Bortezomib The metabolism of Methsuximide can be decreased when combined with Bortezomib.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin glulisine.
Lubiprostone Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Methsuximide.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Oxaliplatin.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Methsuximide.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Primaquine.
Aliskiren Aliskiren The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Aliskiren.
Darunavir Darunavir The serum concentration of Methsuximide can be increased when it is combined with Darunavir.
Dimenhydrinate Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methsuximide.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Methsuximide.
Sorafenib Sorafenib The metabolism of Methsuximide can be decreased when combined with Sorafenib.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Methsuximide.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Lapatinib Lapatinib The metabolism of Lapatinib can be decreased when combined with Methsuximide.
Levocetirizine Levocetirizine The risk or severity of adverse effects can be increased when Methsuximide is combined with Levocetirizine.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Methsuximide.
Mexiletine Mexiletine Mexiletine may increase the arrhythmogenic activities of Methsuximide.
Armodafinil Armodafinil The metabolism of Methsuximide can be decreased when combined with Armodafinil.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Methsuximide.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Toremifene.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Methsuximide can be decreased when combined with Chloramphenicol.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methsuximide.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methsuximide.
Etravirine Etravirine The metabolism of Etravirine can be decreased when combined with Methsuximide.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Methsuximide is combined with Desvenlafaxine.
Nebivolol Nebivolol The risk or severity of bradycardia can be increased when Methsuximide is combined with Nebivolol.
Flecainide Flecainide Methsuximide may increase the arrhythmogenic activities of Flecainide.
Certolizumab Injection Certolizumab Injection The metabolism of Methsuximide can be increased when combined with Certolizumab pegol.
Praziquantel Praziquantel The metabolism of Praziquantel can be decreased when combined with Methsuximide.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Methsuximide.
Silodosin Silodosin The risk or severity of hypotension can be increased when Silodosin is combined with Methsuximide.
Midazolam Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Methsuximide is combined with Milnacipran.
Dexlansoprazole Dexlansoprazole The metabolism of Methsuximide can be decreased when combined with Dexlansoprazole.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methsuximide.
Fesoterodine Fesoterodine Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Degarelix.
Betaxolol Betaxolol The risk or severity of bradycardia can be increased when Methsuximide is combined with Betaxolol.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Iloperidone.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Methsuximide is combined with Lacosamide.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Tolvaptan.
Dronedarone Dronedarone Methsuximide may increase the arrhythmogenic activities of Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methsuximide.
Palonosetron Injection Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Methsuximide.
Saxagliptin Saxagliptin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Saxagliptin.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Romidepsin.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Topotecan Topotecan Methsuximide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Golimumab Injection Golimumab Injection The metabolism of Methsuximide can be increased when combined with Golimumab.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Pazopanib.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Methsuximide.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Methsuximide.
Ulipristal Ulipristal The metabolism of Ulipristal can be increased when combined with Methsuximide.
Levonorgestrel Levonorgestrel The metabolism of Levonorgestrel can be increased when combined with Methsuximide.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Methsuximide.
Liraglutide Injection Liraglutide Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Liraglutide.
Tocilizumab Injection Tocilizumab Injection The metabolism of Methsuximide can be increased when combined with Tocilizumab.
Fingolimod Fingolimod Methsuximide may increase the bradycardic activities of Fingolimod.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Eribulin.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methsuximide.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Methsuximide is combined with Lurasidone.
Vilazodone Vilazodone The risk or severity of adverse effects can be increased when Methsuximide is combined with Vilazodone.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Methsuximide.
Azilsartan Azilsartan The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Azilsartan medoxomil.
Linagliptin Linagliptin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Linagliptin.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Rilpivirine.
Potassium Iodide Potassium Iodide Potassium Iodide may increase the hyperkalemic activities of Methsuximide.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Methsuximide.
Abiraterone Abiraterone The metabolism of Methsuximide can be decreased when combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Triptorelin.
Ruxolitinib Ruxolitinib Ruxolitinib may increase the bradycardic activities of Methsuximide.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Vandetanib.
Clobazam Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Methsuximide.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Vemurafenib.
Vismodegib Vismodegib The metabolism of Methsuximide can be decreased when combined with Vismodegib.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Methsuximide.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Crizotinib.
Cabergoline Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Methsuximide.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Methsuximide.
Enzalutamide Enzalutamide The metabolism of Methsuximide can be increased when combined with Enzalutamide.
Mirabegron Mirabegron The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Mirabegron.
Regorafenib Regorafenib Methsuximide may increase the bradycardic activities of Regorafenib.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methsuximide.
Lorcaserin Lorcaserin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Mecasermin.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Bedaquiline.
Tofacitinib Tofacitinib Methsuximide may increase the bradycardic activities of Tofacitinib.
Alogliptin Alogliptin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Alogliptin.
Pomalidomide Pomalidomide The risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.
Apixaban Apixaban The metabolism of Apixaban can be decreased when combined with Methsuximide.
Canagliflozin Canagliflozin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Canagliflozin.
Dabrafenib Dabrafenib The serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.
Vortioxetine Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Methsuximide.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Ketorolac Injection Ketorolac Injection The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Methsuximide.
Dapagliflozin Dapagliflozin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Dapagliflozin.
Apremilast Apremilast The metabolism of Methsuximide can be increased when combined with Apremilast.
Ceritinib Ceritinib Methsuximide may increase the bradycardic activities of Ceritinib.
Siltuximab Injection Siltuximab Injection The metabolism of Methsuximide can be increased when combined with Siltuximab.
Albiglutide Injection Albiglutide Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Albiglutide.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Methsuximide is combined with Eslicarbazepine.
Testosterone Injection Testosterone Injection The metabolism of Testosterone can be decreased when combined with Methsuximide.
Oritavancin Injection Oritavancin Injection The metabolism of Methsuximide can be decreased when combined with Oritavancin.
Empagliflozin Empagliflozin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Empagliflozin.
Hydrocodone Hydrocodone Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Dulaglutide.
Methamphetamine Methamphetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Methsuximide.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Methsuximide is combined with Tasimelteon.
Lanreotide Injection Lanreotide Injection Methsuximide may increase the bradycardic activities of Lanreotide.
Secukinumab Injection Secukinumab Injection The metabolism of Methsuximide can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Methsuximide.
Insulin Human Inhalation Insulin Human Inhalation The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin human.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Lenvatinib.
Naloxegol Naloxegol The metabolism of Methsuximide can be decreased when combined with Naloxegol.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Methsuximide.
Ivabradine Ivabradine Methsuximide may increase the bradycardic activities of Ivabradine.
Amiloride Amiloride The risk or severity of hyperkalemia can be increased when Amiloride is combined with Methsuximide.
Isavuconazonium Injection Isavuconazonium Injection The therapeutic efficacy of Isavuconazonium can be increased when used in combination with Methsuximide.
Flibanserin Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Methsuximide.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be increased when Methsuximide is combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ziprasidone.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Methsuximide is combined with Cariprazine.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin degludec.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Methsuximide.
Rifapentine Rifapentine The metabolism of Methsuximide can be increased when combined with Rifapentine.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Methsuximide may decrease the nephrotoxic activities of Amphotericin B.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Methsuximide is combined with Brivaracetam.
Midodrine Midodrine Midodrine may increase the bradycardic activities of Methsuximide.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Methsuximide is combined with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methsuximide.
Rucaparib Rucaparib The metabolism of Methsuximide can be decreased when combined with Rucaparib.
Lixisenatide Injection Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Lixisenatide.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Methsuximide.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Deutetrabenazine.
Safinamide Safinamide The metabolism of Methsuximide can be decreased when combined with Safinamide.
Midostaurin Midostaurin The metabolism of Methsuximide can be decreased when combined with Midostaurin.
Enasidenib Enasidenib The metabolism of Methsuximide can be decreased when combined with Enasidenib.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Delafloxacin.
Letermovir Letermovir The metabolism of Methsuximide can be increased when combined with Letermovir.
Semaglutide Injection Semaglutide Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Semaglutide.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The serum concentration of Methsuximide can be increased when it is combined with Apalutamide.
Lofexidine Lofexidine The therapeutic efficacy of Methsuximide can be increased when used in combination with Lofexidine.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ivosidenib.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Methsuximide.
Stiripentol Stiripentol The metabolism of Methsuximide can be decreased when combined with Stiripentol.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Glasdegib.
Lorlatinib Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Methsuximide.
Rifamycin Rifamycin The metabolism of Methsuximide can be increased when combined with Rifamycin.
Prucalopride Prucalopride The therapeutic efficacy of Prucalopride can be decreased when used in combination with Methsuximide.
Magnesium Citrate Magnesium Citrate The risk or severity of hypotension can be increased when Methsuximide is combined with Magnesium citrate.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Methsuximide can be increased when combined with Emapalumab.
Esomeprazole Injection Esomeprazole Injection The metabolism of Methsuximide can be decreased when combined with Esomeprazole.
Alpelisib Alpelisib The metabolism of Methsuximide can be decreased when combined with Alpelisib.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Methsuximide is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of adverse effects can be increased when Methsuximide is combined with Solriamfetol.
Triclabendazole Triclabendazole The metabolism of Methsuximide can be decreased when combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Entrectinib.
Pitolisant Pitolisant Methsuximide may increase the QTc-prolonging activities of Pitolisant.
Fedratinib Fedratinib The metabolism of Fedratinib can be decreased when combined with Methsuximide.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Methsuximide.
Phenytoin Injection Phenytoin Injection The serum concentration of Phenytoin can be increased when it is combined with Methsuximide.
Fosphenytoin Injection Fosphenytoin Injection The serum concentration of Fosphenytoin can be increased when it is combined with Methsuximide.
Voxelotor Voxelotor The metabolism of Voxelotor can be decreased when combined with Methsuximide.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Methsuximide is combined with Lumateperone.
Lasmiditan Lasmiditan The risk or severity of adverse effects can be increased when Methsuximide is combined with Lasmiditan.
Calcium Acetate Calcium Acetate The therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium acetate.
Cenobamate Cenobamate The serum concentration of Cenobamate can be increased when it is combined with Methsuximide.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Methsuximide.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Methsuximide is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of adverse effects can be increased when Fenfluramine is combined with Methsuximide.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Fostemsavir.
Octreotide Octreotide The serum concentration of the active metabolites of Methsuximide can be increased when Methsuximide is used in combination with Octreotide.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Methsuximide can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Relugolix.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The metabolism of Methsuximide can be increased when combined with Drospirenone.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Methsuximide is combined with Viloxazine.
Theophylline Theophylline Methsuximide may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.
Fenoprofen Fenoprofen The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Methsuximide.
Indomethacin Indomethacin The metabolism of Methsuximide can be decreased when combined with Indomethacin.
Mefenamic Acid Mefenamic Acid The risk or severity of hyperkalemia can be increased when Mefenamic acid is combined with Methsuximide.
Naproxen Naproxen The risk or severity of hyperkalemia can be increased when Naproxen is combined with Methsuximide.
Tolmetin Tolmetin The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Methsuximide.
Sulindac Sulindac The risk or severity of hyperkalemia can be increased when Sulindac is combined with Methsuximide.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Methsuximide.
Phenobarbital Phenobarbital The metabolism of Phenobarbital can be decreased when combined with Methsuximide.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Methsuximide.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Methsuximide.
Primidone Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Methsuximide.
Diethylpropion Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Methsuximide.
Chlorpromazine Chlorpromazine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Chlorpromazine.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Methsuximide.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Methsuximide.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Methsuximide.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Methsuximide.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Methsuximide.
Phenoxybenzamine Phenoxybenzamine The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Methsuximide.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Methsuximide.
Codeine Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Methsuximide.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methsuximide.
Bromocriptine Bromocriptine The risk or severity of hypotension can be increased when Bromocriptine is combined with Methsuximide.
Tranylcypromine Tranylcypromine The metabolism of Methsuximide can be decreased when combined with Tranylcypromine.
Phenelzine Phenelzine The metabolism of Methsuximide can be decreased when combined with Phenelzine.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Methsuximide.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methsuximide.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Prochlorperazine Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methsuximide.
Sulfadiazine Sulfadiazine The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Sulfadiazine.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Methsuximide.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide.
Oxybutynin Oxybutynin Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine Benztropine Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
Maprotiline Maprotiline Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ibuprofen Ibuprofen The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Methsuximide.
Trihexyphenidyl Trihexyphenidyl Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Methsuximide.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methsuximide.
Methylphenidate Methylphenidate The therapeutic efficacy of Methsuximide can be decreased when used in combination with Methylphenidate.
Amoxapine Amoxapine Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
Sulfasalazine Sulfasalazine The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Methsuximide.
Carbamazepine Carbamazepine Carbamazepine may increase the Change in thyroid function activities of Methsuximide.
Molindone Molindone The risk or severity of adverse effects can be increased when Molindone is combined with Methsuximide.
Methyldopa Methyldopa Methyldopa may increase the bradycardic activities of Methsuximide.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Methsuximide.
Prazosin Prazosin The risk or severity of hypotension can be increased when Prazosin is combined with Methsuximide.
Cimetidine Cimetidine The serum concentration of Methsuximide can be increased when it is combined with Cimetidine.
Warfarin Warfarin The metabolism of Methsuximide can be decreased when combined with Warfarin.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Methsuximide.
Loperamide Loperamide Methsuximide may increase the arrhythmogenic activities of Loperamide.
Promethazine Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Methsuximide.
Meclofenamate Meclofenamate The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Methsuximide.
Nitrofurantoin Nitrofurantoin The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Methsuximide.
Digoxin Digoxin Methsuximide may increase the arrhythmogenic activities of Digoxin.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Methsuximide.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Chloroquine.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Quinine.
Ethosuximide Ethosuximide Ethosuximide may increase the arrhythmogenic activities of Methsuximide.
Triamterene Triamterene The risk or severity of hyperkalemia can be increased when Triamterene is combined with Methsuximide.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Methsuximide.
Isosorbide Isosorbide The metabolism of Isosorbide can be increased when combined with Methsuximide.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Methsuximide.
Desipramine Desipramine Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Amitriptyline Amitriptyline Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
Imipramine Imipramine The metabolism of Methsuximide can be decreased when combined with Imipramine.
Probenecid Probenecid The metabolism of Methsuximide can be decreased when combined with Probenecid.
Quinidine Quinidine Methsuximide may increase the arrhythmogenic activities of Quinidine.
Procainamide Procainamide Methsuximide may increase the arrhythmogenic activities of Procainamide.
Isoniazid Isoniazid The metabolism of Methsuximide can be decreased when combined with Isoniazid.
Rifampin Rifampin The metabolism of Methsuximide can be increased when combined with Rifampicin.
Disopyramide Disopyramide Methsuximide may increase the arrhythmogenic activities of Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Valproic acid.
Tamoxifen Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Methsuximide.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Methsuximide.
Methimazole Methimazole The metabolism of Methsuximide can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Chlorpropamide.
Tolbutamide Tolbutamide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Tolbutamide.
Tolazamide Tolazamide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Tolazamide.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Methsuximide.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methsuximide.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Methsuximide.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Cyproheptadine Cyproheptadine Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Methsuximide.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Methsuximide.
Dantrolene Dantrolene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Methsuximide.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methsuximide.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Methsuximide.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.
Disulfiram Disulfiram The therapeutic efficacy of Methsuximide can be decreased when used in combination with Disulfiram.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The serum concentration of Propranolol can be increased when it is combined with Methsuximide.
Nortriptyline Nortriptyline Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
Spironolactone Spironolactone The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Methsuximide.
Amphotericin B Injection Amphotericin B Injection Methsuximide may decrease the nephrotoxic activities of Amphotericin B.
Mercaptopurine Mercaptopurine Methsuximide may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.
Nadolol Nadolol The risk or severity of bradycardia can be increased when Methsuximide is combined with Nadolol.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Methsuximide.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Methsuximide.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methsuximide.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Methsuximide.
Flavoxate Flavoxate Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Fluorouracil.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Methsuximide.
Cefotaxime Injection Cefotaxime Injection The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cefotaxime.
Ketoconazole Ketoconazole The metabolism of Methsuximide can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Methsuximide is combined with Pyrantel.
Captopril Captopril The risk or severity of hyperkalemia can be increased when Captopril is combined with Methsuximide.
Metoprolol Metoprolol The risk or severity of bradycardia can be increased when Methsuximide is combined with Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Methsuximide.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.
Aspirin Aspirin The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Methsuximide.
Salsalate Salsalate The risk or severity of hyperkalemia can be increased when Salsalate is combined with Methsuximide.
Chlorambucil Chlorambucil The therapeutic efficacy of Methsuximide can be decreased when used in combination with Chlorambucil.
Alprazolam Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Methsuximide.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Methsuximide.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Methsuximide.
Dicyclomine Dicyclomine Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine Methsuximide may increase the arrhythmogenic activities of Hyoscyamine.
Propantheline Propantheline Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim Trimethoprim The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Methsuximide.
Diltiazem Diltiazem Methsuximide may increase the arrhythmogenic activities of Diltiazem.
Nifedipine Nifedipine Methsuximide may increase the arrhythmogenic activities of Nifedipine.
Timolol Timolol The risk or severity of adverse effects can be increased when Methsuximide is combined with Timolol.
Verapamil Verapamil Verapamil may increase the arrhythmogenic activities of Methsuximide.
Atenolol Atenolol The risk or severity of bradycardia can be increased when Methsuximide is combined with Atenolol.
Pindolol Pindolol The risk or severity of bradycardia can be increased when Methsuximide is combined with Pindolol.
Diflunisal Diflunisal The risk or severity of hyperkalemia can be increased when Diflunisal is combined with Methsuximide.
Piroxicam Piroxicam The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Methsuximide.
Glyburide Glyburide The metabolism of Glyburide can be decreased when combined with Methsuximide.
Glipizide Glipizide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Glipizide.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Methsuximide.
Nafcillin Injection Nafcillin Injection The therapeutic efficacy of Methsuximide can be decreased when used in combination with Nafcillin.
Pentoxifylline Pentoxifylline Methsuximide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Pentamidine.
Labetalol Labetalol The risk or severity of bradycardia can be increased when Labetalol is combined with Methsuximide.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Leuprolide.
Gemfibrozil Gemfibrozil The metabolism of Methsuximide can be decreased when combined with Gemfibrozil.
Ketoprofen Ketoprofen The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Methsuximide.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Pimozide.
Enalapril Enalapril The risk or severity of hyperkalemia can be increased when Enalapril is combined with Methsuximide.
Flurbiprofen Flurbiprofen The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Methsuximide.
Amiodarone Amiodarone The risk or severity of adverse effects can be increased when Methsuximide is combined with Amiodarone.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ciprofloxacin.
Mesalamine Mesalamine The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Methsuximide.
Diclofenac Diclofenac The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Methsuximide.
Fluoxetine Fluoxetine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Nimodipine Nimodipine Methsuximide may increase the arrhythmogenic activities of Nimodipine.
Clozapine Clozapine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Methsuximide.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ofloxacin.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation and hypotension can be increased when Clarithromycin is combined with Methsuximide.
Benazepril Benazepril The risk or severity of hyperkalemia can be increased when Benazepril is combined with Methsuximide.
Etodolac Etodolac The risk or severity of hyperkalemia can be increased when Etodolac is combined with Methsuximide.
Felodipine Felodipine Felodipine may increase the arrhythmogenic activities of Methsuximide.
Fosinopril Fosinopril The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Methsuximide.
Nabumetone Nabumetone The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Methsuximide.
Quinapril Quinapril The risk or severity of hyperkalemia can be increased when Quinapril is combined with Methsuximide.
Ramipril Ramipril The risk or severity of hyperkalemia can be increased when Ramipril is combined with Methsuximide.
Amlodipine Amlodipine Amlodipine may increase the arrhythmogenic activities of Methsuximide.
Teniposide Injection Teniposide Injection The metabolism of Teniposide can be decreased when combined with Methsuximide.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Methsuximide.
Lisinopril Lisinopril The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Methsuximide.
Oxaprozin Oxaprozin The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Methsuximide.
Rifabutin Rifabutin The metabolism of Methsuximide can be increased when combined with Rifabutin.
Sotalol Sotalol The risk or severity of bradycardia can be increased when Methsuximide is combined with Sotalol.
Bisoprolol Bisoprolol The therapeutic efficacy of Methsuximide can be increased when used in combination with Bisoprolol.
Zolpidem Zolpidem Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The risk or severity of hypotension can be increased when Doxazosin is combined with Methsuximide.
Terazosin Terazosin The risk or severity of hypotension can be increased when Terazosin is combined with Methsuximide.
Isradipine Isradipine Isradipine may increase the arrhythmogenic activities of Methsuximide.
Omeprazole Omeprazole The metabolism of Methsuximide can be decreased when combined with Omeprazole.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Methsuximide.
Fluvastatin Fluvastatin The metabolism of Methsuximide can be decreased when combined with Fluvastatin.
Venlafaxine Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Methsuximide.
Fluvoxamine Fluvoxamine The metabolism of Methsuximide can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone The risk or severity of adverse effects can be increased when Methsuximide is combined with Nefazodone.
Lamotrigine Lamotrigine Lamotrigine may increase the arrhythmogenic activities of Methsuximide.
Losartan Losartan Losartan may increase the arrhythmogenic activities of Methsuximide.
Tramadol Tramadol The risk or severity of CNS depression can be increased when Methsuximide is combined with Tramadol.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Methsuximide.
Lansoprazole Lansoprazole The metabolism of Methsuximide can be decreased when combined with Lansoprazole.
Nicardipine Nicardipine Nicardipine may increase the arrhythmogenic activities of Methsuximide.
Bupropion Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with Methsuximide.
Ticlopidine Ticlopidine The metabolism of Methsuximide can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Saquinavir.
Metformin Metformin The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Metformin.
Dalteparin Injection Dalteparin Injection The risk or severity of hyperkalemia can be increased when Methsuximide is combined with Dalteparin.
Nisoldipine Nisoldipine Nisoldipine may increase the arrhythmogenic activities of Methsuximide.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Methsuximide.
Acarbose Acarbose The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Acarbose.
Glimepiride Glimepiride Methsuximide may increase the arrhythmogenic activities of Glimepiride.
Ritonavir Ritonavir The metabolism of Methsuximide can be decreased when combined with Ritonavir.
Clomipramine Clomipramine The metabolism of Methsuximide can be decreased when combined with Clomipramine.
Zafirlukast Zafirlukast The metabolism of Methsuximide can be decreased when combined with Zafirlukast.
Mirtazapine Mirtazapine Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Trandolapril Trandolapril The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Methsuximide.
Topiramate Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Methsuximide.
Valsartan Valsartan The risk or severity of hyperkalemia can be increased when Valsartan is combined with Methsuximide.
Insulin Lispro Injection Insulin Lispro Injection The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin lispro.
Pramipexole Pramipexole Methsuximide may increase the sedative activities of Pramipexole.
Donepezil Donepezil The risk or severity of adverse effects can be increased when Donepezil is combined with Methsuximide.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Methsuximide.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Azithromycin.
Carvedilol Carvedilol The risk or severity of bradycardia can be increased when Carvedilol is combined with Methsuximide.
Nilutamide Nilutamide The metabolism of Methsuximide can be decreased when combined with Nilutamide.
Selegiline Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Methsuximide.
Bicalutamide Bicalutamide The metabolism of Methsuximide can be decreased when combined with Bicalutamide.
Sertraline Sertraline The risk or severity of adverse effects can be increased when Methsuximide is combined with Sertraline.
Propafenone Propafenone The risk or severity of bradycardia can be increased when Methsuximide is combined with Propafenone.
Letrozole Letrozole The metabolism of Methsuximide can be decreased when combined with Letrozole.
Irbesartan Irbesartan The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Methsuximide.
Tamsulosin Tamsulosin The risk or severity of hypotension can be increased when Tamsulosin is combined with Methsuximide.
Ropinirole Ropinirole Methsuximide may increase the sedative activities of Ropinirole.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Quetiapine.
Cetirizine Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Methsuximide.
Paroxetine Paroxetine The risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Methsuximide.
Citalopram Citalopram Methsuximide may increase the QTc-prolonging activities of Citalopram.
Efavirenz Efavirenz The serum concentration of Methsuximide can be decreased when it is combined with Efavirenz.
Sildenafil Sildenafil The metabolism of Methsuximide can be decreased when combined with Sildenafil.
Pioglitazone Pioglitazone The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Pioglitazone.
Celecoxib Celecoxib The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Methsuximide.
Rosiglitazone Rosiglitazone The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Rosiglitazone.
Tolterodine Tolterodine Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide Thalidomide Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Balsalazide Balsalazide The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Methsuximide.
Nateglinide Nateglinide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Nateglinide.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Methsuximide.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Methsuximide.
Rabeprazole Rabeprazole The metabolism of Methsuximide can be decreased when combined with Rabeprazole.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists

Still Confused? Ask the pharmacist a question here!